{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:27:38Z","timestamp":1790814458503,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","award":["ZYYFY2019008"],"award-info":[{"award-number":["ZYYFY2019008"]}],"id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jocn.2020.11.043","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T11:48:20Z","timestamp":1609588100000},"page":"6-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-An","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Dong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jocn.2020.11.043_b0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Longo","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jocn.2020.11.043_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaneurol.2016.4367","article-title":"Rituximab in treatment-refractory myasthenia gravis","volume":"74","author":"Silvestri","year":"2017","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2020.11.043_b0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2020.11.043_b0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2020.11.043_b0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201-202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2020.11.043_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"411","author":"Litchman","year":"2020","journal-title":"J Neurol Sci"},{"issue":"7","key":"10.1016\/j.jocn.2020.11.043_b0035","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s00415-019-09296-y","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study","volume":"266","author":"Singh","year":"2019","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2020.11.043_b0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.nmd.2019.06.002","article-title":"Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis","volume":"29","author":"Roda","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.jocn.2020.11.043_b0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"JND"},{"issue":"1","key":"10.1016\/j.jocn.2020.11.043_b0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody\u2013positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2020.11.043_b0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.jocn.2020.11.043_b0060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jocn.2020.11.043_b0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"10.1016\/j.jocn.2020.11.043_b0070","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jocn.2020.11.043_b0075","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.jocn.2020.11.043_b0080","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jocn.2020.11.043_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s13063-017-2134-x","article-title":"Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial","volume":"18","author":"den Broeder","year":"2017","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.jocn.2020.11.043_b0090","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jocn.2020.11.043_b0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2020.11.043_b0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.jocn.2020.11.043_b0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.jocn.2020.11.043_b0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.jocn.2020.11.043_b0115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results: Rituximab in Refractory MG","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jocn.2020.11.043_b0120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2020.11.043_b0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2020.11.043_b0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review: Rituximab in Myasthenia Gravis","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"18","key":"10.1016\/j.jocn.2020.11.043_b0135","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jocn.2020.11.043_b0140","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/mus.24063","article-title":"Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment: letters to the editor","volume":"48","author":"Yi","year":"2013","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jocn.2020.11.043_b0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin\u201010 producing\u2010B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.jocn.2020.11.043_b0150","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.jocn.2020.11.043_b0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"10.1016\/j.jocn.2020.11.043_b0160","doi-asserted-by":"crossref","first-page":"102349","DOI":"10.1016\/j.autrev.2019.102349","article-title":"HLA in myasthenia gravis: from superficial correlation to underlying mechanism","volume":"18","author":"Zhong","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.jocn.2020.11.043_b0165","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.jocn.2020.11.043_b0170","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4049\/jimmunol.1901176","article-title":"IL-37 represses the autoimmunity in myasthenia gravis via directly targeting follicular Th and B cells","volume":"204","author":"Liu","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2020.11.043_b0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2015.04.004","article-title":"Remarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravis","volume":"283","author":"Zhang","year":"2015","journal-title":"J Neuroimmunol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586820316660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586820316660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:24:12Z","timestamp":1760822652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586820316660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":35,"alternative-id":["S0967586820316660"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2020.11.043","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2020.11.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}